Oracle Stock Draws Fresh Targets As VA Deal Expands

Oracle Corporation stocks have been trading up by 3.21 percent after upbeat cloud growth and AI demand boosted investor confidence.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading ORCL

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For ORCL Traders

The U.S. Department of Veterans Affairs lifted the ceiling on Oracle Health’s EHR modernization deal by $17B to nearly $27B, adding options that extend potential revenue through 2031.
Citi reaffirmed a Buy on ORCL with a $330 target and a 90‑day upside catalyst watch after a sharp selloff, citing powerful AI‑driven demand as the core bull driver.
Jefferies and TD Cowen cut price targets but kept Buy ratings, arguing weak sentiment is largely priced in while cloud and SaaS growth trends challenge the bear case.
EU regulators are informally reviewing Oracle’s software and cloud licensing practices, creating a regulatory overhang but not yet a formal case.
ORCL will report Q1 FY 2027 results after the close on 2026/09/10, a key test of the AI and cloud growth story that traders are leaning on.

Live Update At 09:17:46 EDT: On Friday, September 04, 2026 Oracle Corporation stock [NYSE: ORCL] is trending up by 3.21%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ORCL has been grinding higher again. After sliding into the low $140s in late August, Oracle stock bounced hard, closing near $154.04 on 2026/09/03. That’s a strong move off the recent $139–$142 support zone, and it tells traders that dip buyers are alive and well.

Intraday, ORCL is trading in a tight band between roughly $155 and $159, with repeated holds around $156–$157 in the premarket and early hours. That kind of steady tape often shows accumulation rather than panic. Range traders will see clear levels to lean on, while breakout traders watch the recent $159–$160 area as the next battlefield.

Fundamentally, Oracle Corporation is throwing off serious cash. Trailing revenue sits around $67.4B with double‑digit multi‑year growth. EBIT margin near 36% and profit margins above 25% show a mature, high‑margin software and cloud franchise. The P/E near 25 and price‑to‑sales around 6.2 place ORCL solidly in large‑cap growth territory, not a deep value play.

More Breaking News

Leverage is high, with total debt to equity over 4 and long‑term debt around $96.3B, but interest coverage above 7 and strong operating cash flow support the balance sheet for now. For traders, that means ORCL’s story is still about growth and execution, not survival.

Why Traders Are Watching ORCL Right Now

Oracle Corporation is sitting at the crossroads of three powerful themes: massive government tech spending, an aggressive cloud build‑out, and AI‑driven software demand. That mix is exactly why ORCL keeps showing up on active traders’ screens.

On the government side, the U.S. Department of Veterans Affairs just raised the ceiling on Oracle Health’s electronic health record modernization contract by $17B, taking it to nearly $27B and tacking on three optional one‑year extensions running through 2031. For ORCL, that is not just a headline number. It’s multi‑year, visible federal healthcare revenue, tied to mission‑critical infrastructure. When traders see a contract that large, they see a floor under a piece of the business that can smooth out cyclical cloud swings.

The cloud story is building in parallel. Oracle Cloud Infrastructure is adding more private connectivity by extending CoreSite’s FastConnect service to the San Jose OCI region. That brings ORCL to four directly connected U.S. commercial regions via CoreSite. For enterprise workloads, especially multicloud setups, low‑latency private links matter. Each incremental region tightens Oracle Corporation’s grip in the data‑heavy, AI‑heavy world that big clients care about.

Then there’s validation from the enterprise software side. Oracle was named a Leader in Gartner’s 2026 Magic Quadrant for Supply Chain Management Suites, with Fusion Cloud SCM ranked at the top across several high‑value use cases. Traders watching ORCL are not just buying a legacy database vendor; they are watching a SaaS and AI supply‑chain platform that major analysts say is best‑in‑class. That helps explain why the Street, even after cutting numbers, still leans bullish.

Citi stuck a $330 target on ORCL and slapped it on a 90‑day upside catalyst watch, arguing that strong AI‑related demand and technical capitulation selling set the stage for a rebound. Jefferies trimmed its target to $290 and TD Cowen to $240, but both kept Buy ratings, saying negative sentiment is largely baked in and that an inflection in cloud and SaaS growth can undercut the bearish narrative. Layer that onto a Street‑wide overweight stance with average targets in the mid‑$240s, and traders see a name where most big desks still expect higher levels over time.

There are risks. EU antitrust regulators are informally reviewing Oracle’s software and cloud licensing practices, similar to a recent SAP case that ended with concessions. No formal investigation has started, but headline risk hangs over ORCL, especially in Europe. On the U.S. health‑tech side, Oracle Corporation is also on the radar as the FDA adds a technology‑focused deputy commissioner, which could influence oversight of health data and cloud tools. None of this is thesis‑breaking yet, but short‑term traders should stay alert to regulatory headlines.

All of this funnels into one near‑term catalyst: ORCL’s Q1 FY 2027 earnings release after the close on 2026/09/10, followed by its conference call. That print will show whether AI and cloud demand are actually flowing through to revenue and margins or whether the Street has to cut again. For active traders, that means volatility and opportunity.

Conclusion

ORCL is not a sleepy mega‑cap right now; it’s a battleground between short‑term fear and long‑term conviction. On one side, traders see a heavy debt load, EU regulatory noise, and a seasonally soft quarter ahead. On the other, they see a $27B‑size VA contract, expanding OCI connectivity, Gartner‑certified supply‑chain strength, and a wall of Buy ratings from Citi, Jefferies, TD Cowen, and others.

For short‑term trading, the chart says ORCL is trying to carve out a base in the mid‑$140s to mid‑$150s after a sharp pullback. Tight intraday ranges near $156–$159 suggest accumulation ahead of the 2026/09/10 earnings event. Breakouts above recent highs could feed on themselves if the report backs up the AI and cloud narrative. Failed breakouts, especially if earnings disappoint, may give fast shorts room to work.

Longer term, traders focused on process will watch how Oracle Corporation handles its October 28 analyst day, where TD Cowen expects fresh fiscal 2030 cloud targets. That is where management can reset the trajectory and either rebuild trust or raise new questions.

The mindset matters here. As Tim Sykes loves to say, “Discipline and preparation are what separate consistent traders from the crowd.” As Tim Bohen, lead trainer with StocksToTrade says, “Time and experience have taught me that missed opportunities are part of the game. There’s always another setup around the corner.” ORCL fits that philosophy. Study the news, know the catalysts, map the key levels, and treat every trade in Oracle Corporation as part of a repeatable system, not a lottery ticket. This analysis is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!